论文部分内容阅读
目的观察重组组织型纤溶酶原激活剂(rt.PA)联合丁苯酞治疗急性脑梗死的疗效及安全性。方法回顾性病例研究方法,分析2010年2月—2014年1月40例急性缺血性脑梗死患者的相关资料,并应用rtPA溶栓患者,随机分为治疗组和对照组。治疗组给予rt.PA联合丁苯酞治疗,对照组只给予rt.PA溶栓。比较两组患者治疗后24 h、7 d、1个月及3个月的美国国立卫生研究院卒中量表(NIHSS)评分。结果治疗组与对照组比较,在治疗前、治疗后24 h、7 d NIHSS评分差异无统计学意义;1个月、3个月NIHSS评分比较有统计学意义。结论阿替普酶联合丁苯酞治疗急性脑梗死在远期效果上优于单用阿替普酶治疗。
Objective To observe the efficacy and safety of recombinant tissue plasminogen activator (rt.PA) combined with butylphthalide in the treatment of acute cerebral infarction. Methods A retrospective case study was conducted to analyze the data of 40 patients with acute ischemic cerebral infarction from February 2010 to January 2014 and the patients were randomly divided into treatment group and control group. The treatment group was given rt.PA combined with butylphthalide treatment, the control group was given only rtPAPA thrombolysis. The National Institutes of Health Stroke Scale (NIHSS) score was compared between the two groups at 24 h, 7 d, 1 month, and 3 months after treatment. Results There was no significant difference in NIHSS score between the treatment group and the control group before and 24 h and 7 d after treatment. The NIHSS scores at 1 and 3 months were statistically significant. Conclusion The combination of alteplase and butylphthalide in the treatment of acute cerebral infarction is better than that of alteplase alone in long-term efficacy.